1,216 results on '"Steinhubl, Steven"'
Search Results
152. Uniform platelet acrtivation exists before coronary stent implantation despite aspirin therapy
153. Being Successful at Prevention: Making It Easy to Do the Right Thing: Comment on “Improving Care After Myocardial Infarction Using a 2-Year Internet-Delivered Intervention”
154. High-sensitivity C-reactive protein and clopidogrel treatment in patients at high risk of cardiovascular events: a substudy from the CHARISMA trial
155. Wearable sensor data and self-reported symptoms for COVID-19 detection
156. Screening for atrial fibrillation: predicted sensitivity of short, intermittent electrocardiogram recordings in an asymptomatic at-risk population
157. Passive Monitoring of Physiological Data and Self-reported Symptoms to Detect Clusters of People with COVID-19
158. Pregnancy health in POWERMOM participants living in rural versus urban zip codes
159. Inter- and intraindividual variability in daily resting heart rate and its associations with age, sex, sleep, BMI, and time of year: Retrospective, longitudinal cohort study of 92,457 adults
160. Ethical Considerations When Creating Evidence from Real World Digital Health Data
161. The VerifyNow System
162. Contributors
163. Corrigendum to “Current strategies in antiplatelet therapy — Does identification of risk and adjustment of therapy contribute to more effective, personalized medicine in cardiovascular disease?” [Pharmacol. Ther. 127(2) (2010) 95–107]
164. Current strategies in antiplatelet therapy — Does identification of risk and adjustment of therapy contribute to more effective, personalized medicine in cardiovascular disease?
165. Usability of a Wrist-Worn Smartwatch in a Direct-to-Participant Randomized Pragmatic Clinical Trial
166. Pharmacokinetics and Pharmacodynamics of a Bolus and Infusion of Cangrelor: A Direct, Parenteral P2Y12 Receptor Antagonist
167. Síndromes coronarios agudos
168. Colaboradores
169. Antiplatelet therapy
170. Aspirin following PCI: too much of a good thing?
171. The influence of body mass index on mortality and bleeding among patients with or at high-risk of atherothrombotic disease
172. Aspirin to Prevent Cardiovascular Disease: The Association of Aspirin Dose and Clopidogrel With Thrombosis and Bleeding
173. Cangrelor in percutaneous coronary intervention
174. Impact of anticoagulation regimens on sheath management and bleeding in patients undergoing elective percutaneous coronary intervention in the STEEPLE trial
175. Aspirin and Clopidogrel Resistance: Does it Matter in Clinical Practice?
176. Vulnerable Plaque Intervention: State of The Art
177. Atrial fibrillation in the setting of acute myocardial infarction —irregularly irregular treatment
178. Impact of anticoagulation levels on outcomes in patients undergoing elective percutaneous coronary intervention: insights from the STEEPLE trial
179. Incidence and Prognostic Significance of Thrombocytopenia in Patients Treated With Prolonged Heparin Therapy
180. Digital medicine: Digital health care for older adults
181. Intravenous Low-Molecular-Weight Heparins Compared With Unfractionated Heparin in Percutaneous Coronary Intervention: Quantitative Review of Randomized Trials
182. An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial
183. Aspirin Dose and Cardiovascular Disease Prevention
184. Peroxisome proliferator—activated receptor γ agonists for the Prevention of Adverse events following percutaneous coronary Revascularizationʼresults of the PPAR Study
185. Oral Antiplatelet Therapy for Percutaneous Coronary Revascularization
186. Enoxaparin in Elective Percutaneous Coronary Intervention
187. Early Coronary Revascularization Diminishes the Risk of Ischemic Stroke With Acute Myocardial Infarction
188. Incidence and Prevention of Ischemic Stroke following Myocardial Infarction: Review of Current Literature
189. Low-molecular-weight heparins as adjunctive therapy to thrombolytics: extracting the best data
190. How do low-molecular-weight heparin and unfractionated heparin compare following ST-segment elevation MI?
191. Clopidogrel Treatment Prior to Percutaneous Coronary Intervention: When Enough Isnʼt Enough
192. Clopidogrel Bisulfate In ST-Segment Elevation Myocardial Infarction: A Viewpoint by Steven R. Steinhubl
193. Influence of treatment duration with a 600-mg dose of clopidogrel before percutaneous coronary revascularization
194. Clopidogrel for Percutaneous Coronary Revascularization: Time for More Pretreatment, Retreatment, or Both?
195. Safety and efficacy of aspirin, clopidogrel, and warfarin after coronary stent placement in patients with an indication for anticoagulation
196. Long data from the electrocardiogram
197. Risk reduction with long-term clopidogrel following percutaneous coronary intervention
198. Absence of Interaction Between Atorvastatin or Other Statins and Clopidogrel: Results From the Interaction Study
199. Wearable sensor derived decompensation index for continuous remote monitoring of COVID-19 diagnosed patients.
200. Three year clinical outcomes in a nationwide, observational, siteless clinical trial of atrial fibrillation screening—mHealth Screening to Prevent Strokes (mSToPS).
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.